← Back to Screener
Mirum Pharmaceuticals, Inc. Common Stock (MIRM)
Price$93.48
Value ScoreF
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)20.04%
Price vs S&P 500 (4W)-12.76%
VGM Score55.26
Market Capitalization$5.70B
All Metrics
P/CF (Annual)102.11x
Book Value / Share (Quarterly)$3.98
P/TBV (Annual)75.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)89.13%
Cash Flow / Share (Quarterly)$-3.00
Price vs S&P 500 (YTD)10.19%
Gross Margin (TTM)81.39%
Net Profit Margin (TTM)-140.24%
EPS (TTM)$-13.60
10-Day Avg Trading Volume0.69M
EPS Excl Extra (TTM)$-13.60
EPS (Annual)$-0.47
ROI (Annual)-3.74%
Gross Margin (Annual)80.77%
Net Profit Margin (5Y Avg)-146.63%
Cash / Share (Quarterly)$6.34
Revenue Growth QoQ (YoY)43.28%
ROA (Last FY)-2.77%
Revenue Growth TTM (YoY)50.19%
EBITD / Share (TTM)$-14.21
ROE (5Y Avg)-55.51%
Operating Margin (TTM)-139.82%
Cash Flow / Share (Annual)$1.06
P/B Ratio23.51x
P/B Ratio (Quarterly)22.99x
Net Income / Employee (Annual)$-63,300
EV / Revenue (TTM)9.98x
Net Interest Coverage (TTM)-11.89x
ROA (TTM)-98.48%
EV / EBITDA (TTM)2697.28x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)2.67x
Quick Ratio (Quarterly)1.90x
3-Month Avg Trading Volume0.91M
52-Week Price Return109.36%
EV / Free Cash Flow (Annual)103.62x
Revenue / Employee (TTM)$1,543,700
Tangible BV / Share (Quarterly)$1.04
P/S Ratio (Annual)10.94x
Asset Turnover (Annual)0.62x
52-Week High$114.99
Operating Margin (5Y Avg)-125.44%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)32.91%
26-Week Price Return27.97%
Quick Ratio (Annual)2.46x
13-Week Price Return6.42%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)2.09x
Enterprise Value$5.69B
Asset Turnover (TTM)0.70x
Book Value / Share Growth (5Y)0.98%
Revenue / Employee (Annual)$1,412,800
Inventory Turnover (Annual)4.24x
Pretax Margin (Annual)-4.11%
Cash / Share (Annual)$7.39
3-Month Return Std Dev48.25%
Gross Margin (5Y Avg)81.06%
Net Income / Employee (TTM)$-2,164,900
ROE (Last FY)-7.42%
Net Interest Coverage (Annual)-610.55x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)100.23x
Receivables Turnover (TTM)4.98x
EV / Free Cash Flow (TTM)119.33x
Total Debt / Equity (Quarterly)1.28x
EPS Incl Extra (TTM)$-13.60
Receivables Turnover (Annual)5.17x
ROI (TTM)-136.39%
P/S Ratio (TTM)10.01x
Pretax Margin (5Y Avg)-148.01%
Revenue / Share (Annual)$10.39
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)85.00%
Year-to-Date Return18.34%
5-Day Price Return-2.96%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-21.62%
Net Profit Margin (Annual)-4.48%
Month-to-Date Return-7.90%
Cash Flow / Share (TTM)$-4.10
EBITD / Share (Annual)$0.04
Operating Margin (Annual)-4.25%
LT Debt / Equity (Annual)0.98x
P/CF (TTM)117.05x
ROI (5Y Avg)-43.02%
LT Debt / Equity (Quarterly)1.28x
EPS Basic Excl Extra (TTM)$-13.60
P/TBV (Quarterly)75.93x
P/B Ratio (Annual)12.97x
Inventory Turnover (TTM)4.42x
Pretax Margin (TTM)-140.00%
Book Value / Share (Annual)$6.06
Price vs S&P 500 (13W)-1.83%
Beta0.57x
P/FCF (Annual)103.89x
Revenue / Share (TTM)$9.68
ROE (TTM)-289.33%
52-Week Low$43.50
vGradeF
gGradeB
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.08est. -0.36
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MIRMMirum Pharmaceuticals, Inc. Common Stock | F | B | B | $93.48 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Mirum Pharmaceuticals is a biopharmaceutical company developing therapies for rare and orphan liver diseases. The company markets Livmarli, an FDA-approved bile acid transporter inhibitor for cholestatic pruritus in Alagille syndrome patients. Mirum's pipeline includes maralixibat for pediatric cholestatic liver diseases and volixibat for adult patients with cholestatic conditions.